Affimed N.V. (AFMD)

Trade AFMD now with
10/6/2020 6:34:57 AM Affimed Doses First Patient In Phase 1 Clinical Trial Of Cord Blood-derived Natural Killer Cells With AFM13
8/11/2020 6:41:56 AM Affimed Q2 Net Loss EUR 12.2 Mln Or EUR 0.16 Per Share
8/5/2020 6:43:39 AM Affimed Appoints Annalisa Jenkins And Harry Welten To Its Supervisory Board
6/23/2020 6:46:45 AM Affimed Q1 Net Loss EUR 8.3 Mln Or EUR 0.11/Shr Vs Income Of EUR 1.9 Mln Or EUR 0.03/Shr Last Year
6/22/2020 9:27:04 AM Affimed Presents Data From Two Investigational ICE Developed From Fit-for-purpose ROCK Platform
6/17/2020 6:52:11 AM Affimed Announces Completion Of First Dose Cohort In Phase 1/2a Clinical Trial Of AFM24
6/11/2020 6:35:00 AM Affimed Appoints Angus Smith As CFO
4/2/2020 6:37:00 AM Affimed Provides COVID-19-Related Business Update
3/17/2020 7:50:34 AM Affimed Names Arndt Schottelius Chief Scientific Officer
1/10/2020 6:34:09 AM Affimed N.V. Appoints Andreas Harstrick As Chief Medical Officer, Starting In March 2020
11/19/2019 7:41:57 AM Affimed Q3 Net Loss EUR 10.9 Mln Or EUR 0.17 Per Share
8/7/2019 7:50:17 AM Affimed Q2 Net Loss EUR 10.3 Mln Or EUR 0.17/Shr
11/7/2018 7:48:23 AM Affimed Q3 Net Loss EUR 12.0 Mln Or EUR 0.19 Per Share